Asensus Surgical Inc (AMEX:ASXC)
$ 0.3479 0 (0%) Market Cap: 94.92 Mil Enterprise Value: 107.57 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 16/100

Transenterix Inc at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 04:00PM GMT
Release Date Price: $1.62 (-1.22%)
Anthony Fernando
TransEnterix, Inc. - President, CEO & Director

Good morning. I'm Anthony Fernando. I'm the CEO of TransEnterix. And over the next 10, 15 minutes, I'd just like to tell you a little bit about our company, where we are and where we're going over the next few years. These are some forward-looking statements. At TransEnterix, we believe in digitizing the interface between the surgeon and the patient in a way to increase control, reduce surgical variability and improve patient outcome in a value-based health care setting in a relatively very cost-effective manner. And I'll explain this to you as we go along through this presentation.

So who are we? We have a robotic surgical platform called Senhance. It's the first and only digital laparoscopy platform. There's significant market opportunity in robotics. We are FDA cleared, CE approved and we also have the PMDA approval in Japan. So ramping up our clinical adoption globally right now, and we are also the first and extremely well positioned to bring augmented intelligence in surgical robotics and also machine vision in surgery.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot